Exome and genome sequencing in adults with undiagnosed disease: a prospective cohort study.
clinical genetics
diagnostics tests
genetics
molecular genetics
Journal
Journal of medical genetics
ISSN: 1468-6244
Titre abrégé: J Med Genet
Pays: England
ID NLM: 2985087R
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
21
02
2020
revised:
29
04
2020
accepted:
02
05
2020
pubmed:
26
6
2020
medline:
3
9
2021
entrez:
26
6
2020
Statut:
ppublish
Résumé
Exome and genome sequencing have been demonstrated to increase diagnostic yield in paediatric populations, improving treatment options and providing risk information for relatives. There are limited studies examining the clinical utility of these tests in adults, who currently have limited access to this technology. Patients from adult and cancer genetics clinics across Toronto, Ontario, Canada were recruited into a prospective cohort study evaluating the diagnostic utility of exome and genome sequencing in adults. Eligible patients were ≥18 years of age and suspected of having a hereditary disorder but had received previous uninformative genetic test results. In total, we examined the diagnostic utility of exome and genome sequencing in 47 probands and 34 of their relatives who consented to participate and underwent exome or genome sequencing. Overall, 17% (8/47) of probands had a pathogenic or likely pathogenic variant identified in a gene associated with their primary indication for testing. The diagnostic yield for patients with a cancer history was similar to the yield for patients with a non-cancer history (4/18 (22%) vs 4/29 (14%)). An additional 24 probands (51%) had an inconclusive result. Secondary findings were identified in 10 patients (21%); three had medically actionable results. This study lends evidence to the diagnostic utility of exome or genome sequencing in an undiagnosed adult population. The significant increase in diagnostic yield warrants the use of this technology. The identification and communication of secondary findings may provide added value when using this testing modality as a first-line test.
Sections du résumé
BACKGROUND
Exome and genome sequencing have been demonstrated to increase diagnostic yield in paediatric populations, improving treatment options and providing risk information for relatives. There are limited studies examining the clinical utility of these tests in adults, who currently have limited access to this technology.
METHODS
Patients from adult and cancer genetics clinics across Toronto, Ontario, Canada were recruited into a prospective cohort study evaluating the diagnostic utility of exome and genome sequencing in adults. Eligible patients were ≥18 years of age and suspected of having a hereditary disorder but had received previous uninformative genetic test results. In total, we examined the diagnostic utility of exome and genome sequencing in 47 probands and 34 of their relatives who consented to participate and underwent exome or genome sequencing.
RESULTS
Overall, 17% (8/47) of probands had a pathogenic or likely pathogenic variant identified in a gene associated with their primary indication for testing. The diagnostic yield for patients with a cancer history was similar to the yield for patients with a non-cancer history (4/18 (22%) vs 4/29 (14%)). An additional 24 probands (51%) had an inconclusive result. Secondary findings were identified in 10 patients (21%); three had medically actionable results.
CONCLUSIONS
This study lends evidence to the diagnostic utility of exome or genome sequencing in an undiagnosed adult population. The significant increase in diagnostic yield warrants the use of this technology. The identification and communication of secondary findings may provide added value when using this testing modality as a first-line test.
Identifiants
pubmed: 32581083
pii: jmedgenet-2020-106936
doi: 10.1136/jmedgenet-2020-106936
pmc: PMC8475751
mid: NIHMS1720759
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
275-283Subventions
Organisme : NHGRI NIH HHS
ID : UM1 HG008900
Pays : United States
Organisme : CIHR
ID : FRN135730
Pays : Canada
Informations de copyright
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Genet Med. 2017 Aug;19(8):867-874
pubmed: 28125081
Europace. 2018 Oct 1;20(10):1692-1698
pubmed: 29579189
Epilepsia. 2013 Jul;54(7):1270-81
pubmed: 23647072
Clin Genet. 2015 Oct;88(4):313-9
pubmed: 25421945
NPJ Genom Med. 2016 Jan 13;1:
pubmed: 28567303
Clin Genet. 2013 Nov;84(5):453-63
pubmed: 24033266
Front Neurol. 2019 May 21;10:434
pubmed: 31164858
Genet Med. 2019 May;21(5):1100-1110
pubmed: 30287922
Neurology. 2019 Jan 4;:
pubmed: 30610098
Circ Cardiovasc Genet. 2017 Feb;10(1):
pubmed: 28087566
Neurology. 2013 Nov 5;81(19):1697-703
pubmed: 24107868
MDM Policy Pract. 2019 Feb 01;4(1):2381468318821103
pubmed: 30746499
CMAJ. 2002 Oct 29;167(9):1021-9
pubmed: 12403743
Genet Med. 2015 Jul;17(7):578-86
pubmed: 25356970
Genet Med. 2006 Aug;8(8):474-90
pubmed: 16912579
J Child Neurol. 2016 Dec;31(14):1534-1539
pubmed: 27572814
Am J Hum Genet. 2013 Oct 3;93(4):631-40
pubmed: 24055113
Clin Genet. 2016 Jun;89(6):700-7
pubmed: 26757139
Nephron. 2019;142(4):351-358
pubmed: 31096240
Genet Med. 2018 Oct;20(10):1122-1130
pubmed: 29446766
Fam Cancer. 2015 Mar;14(1):69-75
pubmed: 25380764
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Brain. 2016 Nov 1;139(11):2844-2854
pubmed: 27604308
J Med Genet. 2015 Jul;52(7):431-7
pubmed: 25951830
Am J Hum Genet. 2016 Nov 3;99(5):1005-1014
pubmed: 27745832
JAMA Pediatr. 2017 Sep 1;171(9):855-862
pubmed: 28759686
Genet Med. 2017 Sep;19(9):1055-1063
pubmed: 28333917
Genome Med. 2015 Jun 13;7(1):54
pubmed: 26195989
Genome Res. 2015 Mar;25(3):305-15
pubmed: 25637381
Genet Med. 2016 Jul;18(7):678-85
pubmed: 26633545
Clin Kidney J. 2018 Apr;11(2):179-190
pubmed: 29644057
Genet Med. 2016 Nov;18(11):1090-1096
pubmed: 26938784
Genet Med. 2017 Feb;19(2):249-255
pubmed: 27854360